"The Recovery Collaborative Group." (2020). Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2021436 

Kenyon College

This category classifies scholarly articles and references published in *The New England Journal of Medicine* that investigate the pharmacology and drug treatments of COVID-19.

COVID-19 Pharmacology Articles from The New England Journal of Medicine

Boulware, D., Pullen, M., Bangdiwala, A., Pastick, K., Lofgren, S., Okafor, E., Skipper, C., Nascene, A., Nicol, M., Abassi, M., Engen, N., Cheng, M., LaBar, D., Lother, S., MacKenzie, L., Drobot, G., Marten, N., Zarychanski, R., Kelly, L., Schwartz, I., McDonald, E., Rajasingham, R., Lee, T., & Hullsiek, K. (2020). A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2016638. https://www.nejm.org/doi/full/10.1056/NEJMoa2016638

A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H.,  Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z.,  Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F., Horby, P., Zhang, D. & Wang, C. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2001282 

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Cohen, M. (2020). Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence. The New England Journal of Medicine. DOI: 10.1056/NEJMe2020388 

Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence

Cavalcanti, A., Zampieri, F., Rosa, R., Azevedo, L., Veiga, V., Avezum, A., Damiani, L., Marcadenti, A., Kawano-Dourado, L., Lisboa, T., Junqueira, D., de Barros e Silva, P., Tramujas, L., Abreu-Silva, E., Laranjeira, L., Soares, A., Echenique, L., Pereira, A., Freitas, F., Gebara, O., Dantas, V., Furtado, R., Milan, E., Golin, N., Cardoso, F., Maia, I., Filho, C., Kormann, A., Amazonas, R., Bocchi de Oliveira, M., Serpa-Neto, A., Falavigna, M., Lopes, R., Machado, F., & Berwanger, O. (2020). Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2019014. https://www.nejm.org/doi/full/10.1056/NEJMoa2019014

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Goldman, J., Lye, D., Hui, D., Marks, K., Bruno, R., Montejano, R., Spinner, C., Galli, M., Ahn, M., Nahass, R., Chen, Y., SenGupta, D., Hyland, R., Osinusi, A., Cao, H., Blair, C., Wei, X., Gaggar, A., Brainard, D., Towner, W., Muñoz, J., Mullane, K., Marty, F., Tashima, K., Diaz, G., & Subramanian, A. (2020). Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *The New England Journal of Medicine*. https://doi.org/10.1056/NEJMoa2015301

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Geleris, J., Sun, Y., Platt, J., Zucker, J., Baldwin, M., Hripcsak, G., Labella, A., Manson, D., Kubin, C., Barr, R., Sobieszczyk, M., & Schluger, N. ((2020). Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2012410 
https://www.nejm.org/doi/full/10.1056/nejmoa2012410

Learn Before

Related